Wegovy (semaglutide 2.4mg) is a once-weekly injectable GLP-1 receptor agonist from Novo Nordisk, FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Wegovy contains the same active ingredient as Ozempic but reaches a higher maximum dose (2.4mg vs. 2mg), which is reflected in the STEP clinical trial program showing an average 14.9% body weight reduction over 68 weeks. Because the side effect profile scales with dose, understanding what to expect at each stage -- and having clinical support to manage it -- is essential for staying on track through the full escalation.
Wegovy side effects include nausea (44%), diarrhea (30%), and vomiting (24%) based on FDA clinical trial data. Most side effects are mild to moderate and decrease over time. Weight Method prescribes Wegovy through licensed providers with ongoing medical monitoring.
Key Fact
In STEP trials, 44% of Wegovy patients reported nausea, 30% diarrhea, and 24% vomiting — most mild-to-moderate and resolving within weeks. Serious adverse events (pancreatitis, gallbladder disease) occurred in <1% of participants.
Source: Wegovy FDA prescribing information; STEP trials
Nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) were the most common Wegovy side effects in the STEP 1 trial, mostly mild-to-moderate and transient.
In the STEP 1 trial, the most common side effects of Wegovy were nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%) -- though these headline numbers include any occurrence throughout the entire 68-week study, including transient episodes during dose increases. At any given dose level, most patients experience these effects as mild-to-moderate and time-limited, peaking in the first one to two weeks after each escalation. Fatigue, headache, dizziness, and bloating were also reported at rates above placebo. Injection site reactions such as redness or itching occurred in approximately 3.2% of participants.
Serious but rare risks include pancreatitis, gallbladder disease, kidney injury, thyroid tumors (boxed warning), and suicidal ideation — though no causal link is established for the latter.
Wegovy carries the same boxed warning as Ozempic regarding thyroid C-cell tumors, including medullary thyroid carcinoma, and is contraindicated in patients with a personal or family history of MTC or MEN 2. Serious adverse events reported in the STEP trials include acute pancreatitis, acute gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury related to dehydration from GI symptoms, and suicidal ideation or behavior -- though the FDA has not established a causal relationship with the latter. The higher maximum dose of Wegovy compared to Ozempic means that vigilant monitoring during the final escalation steps is particularly important.
Wegovy's five-step dose escalation over 16-20 weeks is the primary defense — your provider can extend any step, and smaller meals with adequate hydration reduce GI symptoms.
Wegovy uses a five-step dose-escalation schedule over 16 to 20 weeks: 0.25mg for four weeks, 0.5mg for four weeks, 1mg for four weeks, 1.7mg for four weeks, then the maintenance dose of 2.4mg. This gradual ramp-up is the single most effective strategy for minimizing side effects -- clinical data shows significantly lower dropout rates among patients who follow the protocol versus those who escalate too quickly. Your Weight Method provider may extend any escalation step by two to four weeks if GI symptoms are bothersome, and can prescribe supportive measures such as anti-nausea strategies. Eating smaller portions, avoiding carbonated beverages, and timing meals to avoid eating when nauseous are practical steps that patients report as highly effective.
Seek immediate care for severe abdominal pain, allergic reactions, persistent vomiting preventing hydration, gallbladder symptoms, mood changes, or a neck lump with voice changes.
Seek medical attention immediately if you develop severe, persistent abdominal pain (a potential sign of pancreatitis), any symptoms of a serious allergic reaction (facial swelling, difficulty breathing, rapid heartbeat, severe rash), or signs of kidney problems such as significantly reduced urination. Contact your Weight Method provider if you experience persistent vomiting or diarrhea that prevents you from staying hydrated, symptoms of gallbladder disease (steady upper-right abdominal pain, especially after eating), any new or worsening mood changes, or a lump or swelling in your neck with hoarseness or trouble swallowing. Your care team is available between scheduled check-ins for exactly these situations.
Take our 2-minute quiz to see if you qualify for GLP-1 treatment.
Start QuizFree consultation. No commitment.